Monogram launches PhenoSense Integrase for HIV in US
This article was originally published in Clinica
Executive Summary
Monogram Biosciences has launched its PhenoSense Integrase assay in the US. The CLIA-validated test measures the susceptibility of HIV to a class of drugs called integrase inhibitors. Merck & Co's Isentress (raltegravir) was the first integrase inhibitor to be US FDA approved, in October 2007. Others in development include Gilead Sciences' GS 9137 (elvitegravir), currently in phase III trials. The drugs block viral replication by inhibiting the insertion of HIV DNA into human DNA by the integrase enzyme. Many older HIV drugs inhibit reverse transcriptase, another enzyme essential for viral replication. PhenoSense Integrase is the only commercially-available integrase inhibitor resistance assay, San Francisco-based Monogram claims. The firm provides the test through its own laboratory.
You may also be interested in...
What are the hottest innovations from Israel?
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
EuroPCR: St Jude and Philips talk up rival intravascular imaging techs
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
EuroPCR: Medtronic's drug-coated balloon keeps rising
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.